Riverbridge Partners LLC reduced its stake in Teladoc Inc (NYSE:TDOC) by 1.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 874,089 shares of the health services provider’s stock after selling 11,070 shares during the quarter. Riverbridge Partners LLC owned about 1.40% of Teladoc worth $50,741,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in the stock. Brown Advisory Inc. bought a new position in Teladoc in the 1st quarter valued at approximately $296,000. Allianz Asset Management GmbH lifted its position in Teladoc by 25.8% in the 1st quarter. Allianz Asset Management GmbH now owns 34,745 shares of the health services provider’s stock valued at $1,401,000 after acquiring an additional 7,116 shares in the last quarter. Principal Financial Group Inc. lifted its position in Teladoc by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 118,266 shares of the health services provider’s stock valued at $4,767,000 after acquiring an additional 3,839 shares in the last quarter. WINTON GROUP Ltd bought a new position in Teladoc in the 1st quarter valued at approximately $238,000. Finally, Levin Capital Strategies L.P. bought a new position in Teladoc in the 1st quarter valued at approximately $403,000.
A number of equities research analysts have weighed in on TDOC shares. SunTrust Banks boosted their target price on shares of Teladoc to $48.00 and gave the company a “positive” rating in a research note on Wednesday, May 2nd. KeyCorp reiterated an “overweight” rating and set a $50.00 target price (up from $41.00) on shares of Teladoc in a research note on Thursday, March 15th. Deutsche Bank boosted their target price on shares of Teladoc from $45.00 to $56.00 and gave the company a “hold” rating in a research note on Thursday, June 7th. Citigroup boosted their target price on shares of Teladoc to $62.00 and gave the company a “buy” rating in a research note on Tuesday, June 5th. Finally, Wells Fargo & Co set a $46.00 target price on shares of Teladoc and gave the company a “buy” rating in a research note on Friday, April 6th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teladoc currently has an average rating of “Buy” and a consensus price target of $49.61.
Shares of NYSE:TDOC traded down $0.05 during midday trading on Tuesday, hitting $59.35. The company had a trading volume of 13,760 shares, compared to its average volume of 1,458,432. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.15 and a quick ratio of 4.15. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of -36.03 and a beta of 0.41. Teladoc Inc has a 12-month low of $27.30 and a 12-month high of $63.65.
Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The firm had revenue of $89.64 million during the quarter, compared to analyst estimates of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. Teladoc’s revenue was up 109.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) EPS. equities research analysts expect that Teladoc Inc will post -1.45 earnings per share for the current fiscal year.
In related news, VP Mark Hirschhorn sold 69,460 shares of the company’s stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $43.73, for a total value of $3,037,485.80. Following the completion of the transaction, the vice president now owns 50,042 shares of the company’s stock, valued at approximately $2,188,336.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jason N. Gorevic sold 25,000 shares of the company’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $41.36, for a total transaction of $1,034,000.00. Following the completion of the transaction, the chief executive officer now directly owns 661,184 shares of the company’s stock, valued at approximately $27,346,570.24. The disclosure for this sale can be found here. Insiders sold a total of 144,460 shares of company stock valued at $6,799,986 over the last 90 days. 3.95% of the stock is currently owned by company insiders.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.